Cargando…
In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)
OBJECTIVES: We investigated the in vitro antimicrobial susceptibilities of clinically important Gram-negative bacteria (GNB) from 16 major teaching hospitals in Taiwan in 2017. MATERIALS AND METHODS: Escherichia coli (n=686) and Klebsiella pneumoniae bloodstream isolates (n=673), non-typhoid Salmone...
Autores principales: | Jean, Shio-Shin, Lu, Min-Chi, Shi, Zhi-Yuan, Tseng, Shu-Hui, Wu, Ting-Shu, Lu, Po-Liang, Shao, Pei-Lan, Ko, Wen-Chien, Wang, Fu-Der, Hsueh, Po-Ren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208934/ https://www.ncbi.nlm.nih.gov/pubmed/30464540 http://dx.doi.org/10.2147/IDR.S175679 |
Ejemplares similares
-
Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020) -
Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016) -
Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
por: Criscuolo, Marianna, et al.
Publicado: (2020) -
Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria
por: Gonzalez, Mark D., et al.
Publicado: (2017) -
Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil
por: Carvalho, Thaisa Noceti, et al.
Publicado: (2023)